clinical trial · NCT06109181
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
Arrhythmogenic CardiomyopathyPKP2-ACMPKP2-ARVCLX2020
brief summary
This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
started
Feb 29, 2024
primary completion
Dec 1, 2026
completion
Mar 1, 2027
last updated
Nov 12, 2025
official title
A Phase 1/2 Study of the Safety and Efficacy of LX2020 Gene Therapy in Patients With Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol